Ori Biotech Ltd, a London, UK-and New Jersey-based cell and gene therapy (CGT) manufacturing company, closed a $30m Series A financing round, bringing total funding to date to $41m.
The round was led by Northpond Ventures, alongside Octopus Ventures, with participation from existing institutional investors Amadeus Capital Partners, Delin Ventures, and Kindred Capital.
The company intends to use the funds to bring its manufacturing platform to the market.
The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.
Led by Jason C. Foster, CEO, and Dr. Farlan Veraitch, Co-Founder and Chief Scientific Officer, Ori Biotech cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing.
The company has brought together a seasoned board and executive management team with over 100 years of pharmaceutical, cell therapy and venture building experience, including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec) and Tom Heathman (HCATS) alongside industry-leading expert advisors like Bruce Levine, Annalisa Jenkins and Anthony Davies.